See more : Infinya Ltd (INFN.TA) Income Statement Analysis – Financial Results
Complete financial analysis of Arvinas, Inc. (ARVN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Arvinas, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Fandifi Technology Corp. (FDMSF) Income Statement Analysis – Financial Results
- Evolv Technologies Holdings, Inc. (EVLV) Income Statement Analysis – Financial Results
- Beam Therapeutics Inc. (BEAM) Income Statement Analysis – Financial Results
- BASF India Limited (BASF.BO) Income Statement Analysis – Financial Results
- Net Insight AB (publ) (0H14.L) Income Statement Analysis – Financial Results
Arvinas, Inc. (ARVN)
About Arvinas, Inc.
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 78.50M | 131.40M | 46.70M | 21.80M | 42.98M | 14.32M | 7.58M | 6.67M |
| Cost of Revenue | 0.00 | 8.20M | 6.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 78.50M | 123.20M | 40.70M | 21.80M | 42.98M | 14.32M | 7.58M | 6.67M |
| Gross Profit Ratio | 100.00% | 93.76% | 87.15% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 379.70M | 315.00M | 180.40M | 108.36M | 67.19M | 45.19M | 28.79M | 19.94M |
| General & Administrative | 100.30M | 79.60M | 61.60M | 38.30M | 27.31M | 12.93M | 3.55M | 3.20M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 100.30M | 79.60M | 61.60M | 38.30M | 27.31M | 12.93M | 3.55M | 3.20M |
| Other Expenses | 0.00 | 200.00K | 2.50M | 2.00M | 1.44M | 102.73K | 554.16K | 1.66M |
| Operating Expenses | 480.00M | 394.60M | 242.00M | 146.66M | 94.50M | 58.13M | 32.34M | 23.14M |
| Cost & Expenses | 480.00M | 394.60M | 242.00M | 146.66M | 94.50M | 58.13M | 32.34M | 23.14M |
| Interest Income | 38.80M | 12.20M | 4.30M | 5.53M | 5.91M | 2.32M | 201.39K | 427.77K |
| Interest Expense | 0.00 | 12.00M | 100.00K | 65.00K | 85.57K | 57.44K | 50.36K | 67.40K |
| Depreciation & Amortization | 6.70M | 8.20M | 6.00M | 4.02M | 2.25M | 706.00K | 347.40K | 436.33K |
| EBITDA | -394.80M | -256.90M | -183.60M | -117.60M | -67.95M | -40.72M | -23.65M | -13.93M |
| EBITDA Ratio | -502.93% | -200.30% | -418.20% | -572.69% | -119.89% | -305.80% | -312.15% | -209.16% |
| Operating Income | -401.50M | -263.20M | -195.30M | -124.86M | -51.52M | -43.80M | -24.76M | -16.47M |
| Operating Income Ratio | -511.46% | -200.30% | -418.20% | -572.69% | -119.89% | -305.80% | -326.70% | -246.95% |
| Total Other Income/Expenses | 37.60M | 12.20M | -2.60M | 1.50M | -18.79M | 2.32M | 711.06K | 2.03M |
| Income Before Tax | -363.90M | -251.00M | -191.00M | -119.33M | -70.29M | -41.48M | -24.05M | -14.44M |
| Income Before Tax Ratio | -463.57% | -191.02% | -408.99% | -547.35% | -163.56% | -289.59% | -317.32% | -216.49% |
| Income Tax Expense | 900.00K | 20.90M | -7.80M | -7.55M | -8.16M | 2.38M | 604.52K | -87.41K |
| Net Income | -367.30M | -271.90M | -183.20M | -111.79M | -62.13M | -41.48M | -24.05M | -14.35M |
| Net Income Ratio | -467.90% | -206.93% | -392.29% | -512.74% | -144.57% | -289.59% | -317.32% | -215.18% |
| EPS | -6.62 | -5.11 | -3.66 | -2.83 | -1.89 | -4.40 | -1.16 | -0.80 |
| EPS Diluted | -6.62 | -5.11 | -3.66 | -2.83 | -1.89 | -4.40 | -1.16 | -0.80 |
| Weighted Avg Shares Out | 55.50M | 53.20M | 50.00M | 39.53M | 32.93M | 9.42M | 20.73M | 17.88M |
| Weighted Avg Shares Out (Dil) | 55.50M | 53.20M | 50.00M | 39.53M | 32.93M | 9.42M | 20.73M | 17.88M |
Arvinas and Pfizer Announce Updated Vepdegestrant (ARV-471) Data to be Presented at the 2023 San Antonio Breast Cancer Symposium
-- Six abstracts have been accepted for presentation, including updated data on vepdegestrant alone and in combination with palbociclib (IBRANCE®) -- NEW HAVEN, Conn. and NEW YORK, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc....
Arvinas Announces Oversubscribed $350 Million Private Placement
NEW HAVEN, Conn., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that it has entered into a securities purchase agreement with a...
Arvinas: Protein Degradation Pioneer Presents An Intriguing Speculative Buy Opportunity
Arvinas is a leading company in developing protein degraders, with a depressed share price, drugs in advanced study phases, and ample cash reserves. Arvinas is focused on oncology, particularly breast and prostate cancer, setting it apart from competitor Kymera. The...
Wall Street Analysts Predict a 165.07% Upside in Arvinas, Inc. (ARVN): Here's What You Should Know
The mean of analysts' price targets for Arvinas, Inc. (ARVN) points to a 165.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside...
Arvinas, Inc. (ARVN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Arvinas, Inc. (ARVN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher...
Arvinas Reports Third Quarter 2023 Financial Results and Provides Corporate Update
– Enrollment continues in the 2L Phase 3 VERITAC-2 trial and study lead-in for the VERITAC-3 1L Phase 3 trial with vepdegestrant; Top-line data readout for VERITAC-2 remains on-track for 2H 2024 –
Arvinas to Participate in Upcoming Investor Conferences
NEW HAVEN, Conn., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in five upcoming investor conferences:
Strength Seen in Arvinas, Inc. (ARVN): Can Its 6.3% Jump Turn into More Strength?
Arvinas, Inc. (ARVN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Potential of Arvinas' PROTAC® AR Degraders Reinforced by 11.1 months rPFS with Bavdegalutamide and Updated Positive Interim Data from Second Generation ARV-766 in mCRPC
– Data presented at the European Society for Medical Oncology from the Phase 1/2 trial with bavdegalutamide showed 11.1 months radiographic progression free survival in mCRPC patients with tumors harboring AR 878/875 mutations –
Arvinas Gives Back to Local Greater New Haven Community in Second Annual Impact Day
NEW HAVEN, Conn., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that nearly 200 employees participated in the Company's second annual...
Source: https://incomestatements.info
Category: Stock Reports